湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 说明： 1、主营业务分行业情况中，"医疗业务及其他"为子公司永州方盛天鸿肿瘤医院 有限公司医疗服务业务收入、子公司重庆筱熊猫药业股份有限公司和湖南方盛锐新药业 有限公司（分别于 2024 年 4 月、6 月后不再纳入合并范围）医药销售业务收入、子公司 广东暨大基因药物工程研究中心有限公司的医药技术服务收入、子公司云南芙雅生物科 技有限公司植物提取产品收入； 证券代码：603998 证券简称：方盛制药 公告编号：2025-077 湖南方盛制药股份有限公司 2025年半年度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司行业信息披露指引第六号——医药制造》的 相关规定，湖南方盛制药股份有限公司（以下简称"公司"）现 将 2025 年上半年度主要经营数据披露如下（单位：元，人民币）： | | | ...

Core Insights - The National Healthcare Security Administration released the "2024 National Medical Security Development Statistical Bulletin," highlighting key data on healthcare insurance in China [1] Group 1: Healthcare Insurance Participation and Financials - As of the end of 2024, the number of participants in the basic medical insurance scheme reached 1.32662 billion, maintaining a coverage rate of 95% [2] - Total revenue for the basic medical insurance fund (including maternity insurance) was 3.491337 trillion yuan, while total expenditures were 2.976403 trillion yuan, resulting in a surplus of 463.917 billion yuan for the year [2] Group 2: Employee Insurance and Maternity Benefits - The number of participants in employee medical insurance reached 379.4834 million, an increase of 8.537 million or 2.3% from the previous year, with over 104.575 million retirees covered [5] - The number of individuals enjoying maternity insurance benefits increased by 3.9638 million, a growth of 1.6%, with 36.908 million instances of benefits claimed, marking a 30.2% increase [6] Group 3: Fraud Prevention and Recovery - The healthcare system recovered 27.5 billion yuan in fraud cases, with 2,008 institutions confirmed for fraud, and 10,741 suspects arrested [8] Group 4: Drug Inclusion and Procurement - A total of 3,159 drugs are included in the 2024 National Basic Medical Insurance Drug List, with 91 new drugs added this year [9][10] - Since the establishment of the National Healthcare Security Administration in 2018, 835 drugs have been added to the insurance list, with 2.8 billion instances of drug reimbursement in 2024 [10] Group 5: Long-term Care Insurance - Participation in long-term care insurance reached 187.8634 million in 49 pilot cities, with the number of beneficiaries increasing from 835,000 in 2020 to 1.4625 million in 2024 [11] Group 6: Cross-Region Medical Services - In 2024, there were 397 million instances of cross-region medical services, with total costs amounting to 786.774 billion yuan [13]